Personalis Inc. (PSNL)
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.23 per share a year ago.
Personalis, Inc. (PSNL) M&A Call Transcript
Personalis, Inc. (PSNL) M&A Call Transcript
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a 28% premium to the unaffected 30-day volume-weighted average price.
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap.
Personalis Q1 Earnings Call Highlights
Personalis NASDAQ: PSNL reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and biopharma MRD programs over lower-margin legacy enterprise revenue.
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.18 per share a year ago.
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.23 per share a year ago.
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Personalis, Inc. ( PSNL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Christopher Hall - President, CEO & Director Aaron Tachibana - CFO & COO Richard Chen - Executive VP of R&D and Chief Medical Officer Conference Call Participants Caroline Corner - Westwicke Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Michael Matson - Needham & Company, LLC, Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Personalis Third Quarter 2025 Earnings Conference.
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.64 per share a year ago.
